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Abstract
Background: Heme oxygenase (HO)-1 has been shown to attenuate oxidative injury and reduce apoptosis. HO-1
can be induced by various stimuli released during cellular injury, such as heme. Deleterious free heme is degraded
by HO-1 to carbon monoxide, iron and biliverdin, which have potent anti-oxidant and anti-inflammatory properties.
In this study, we tested the hypothesis that upregulation of HO-1 would inhibit production of the free radical (NO)
by interlukin (IL)-1b-activated human astrocytes.
Methods: To measure NO production, inducible NO synthase (iNOS), HO-1 expression and mitogen-activated
protein (MAP) kinase activation we used hemin as an HO-1 inducer and tin protoporphyrin (SnPP) IX as an
inhibitor of HO-1 activity in human astrocyte cultures prior to IL-1b exposure. Transfection of astrocyte cultures was
performed using a pLEX expression vector carrying the human HO-1 sequence prior to IL-1b treatment.
Supernatants of astrocyte cultures pretreated with inhibitors of p38 MAPK or MEK1/2 prior to IL-1b exposure were
collected for NO assay.
Results: IL-1b treatment of astrocytes alone induced undetectable amounts of HO-1 protein by western blot.
However, HO-1 mRNA expression was modestly up-regulated in response to IL-1b stimulation. Pretreatment with
hemin alone substantially induced both HO-1 mRNA and protein expression, and HO-1 mRNA expression was
further enhanced when hemin was combined with IL-1b treatment. In contrast, IL-1b-induced iNOS mRNA
expression and NO production were markedly inhibited by hemin treatment. When pretreated with SnPP, the
inhibitory effect of hemin on IL-1b-induced NO production and iNOS expression was reversed, suggesting the
involvement of HO-1. IL-1b-induced p38 MAPK activation, which is known to be required for NO production, was
also down-regulated by hemin.
Conclusion: These findings support the hypothesis that up-regulation of HO-1 in astrocytes is associated with
down-regulation of iNOS expression and thereby NO production, an effect that involves the p38 MAPK signaling
pathway, which suggests that this glial cell response could play an important protective role against oxidative
stress in the brain.
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Hemin (ferriprotoporphyrin IX chloride), the oxidized
form of the heme moiety of hemoglobin and a constitu-
ent of many enzymes, is degraded by heme oxygenase
(HO)-1, which in turn generates carbon monoxide
(CO), iron and biliverdin. While CO and biliverdin each
have cytoprotective and anti-inflammatory properties,
iron is sequestered by ferritin to reduce free radical for-
mation and later utilized to maintain iron homeostasis
for gene regulation. Hemin has been reported to sup-
press human immunodeficiency virus (HIV)-1 infection
of human monocytes through HO-1 induction [1], but
has also been reported to induce necroptosis of murine
cortical astrocytes [2] and oxidative injury to human
neurons [3]. In a recent study hemin was used to induce
HO-1 in humans [4].
Under conditions of oxidative stress, induction of HO-
1i se v i d e n t ,a n di t sa n t i - o x i d a n tp r o p e r t i e sa r et h o u g h t
to contribute to balancing the redox environment. HO-
1, which is the inducible isoform of the stress response
protein HO that detoxifies heme, can be induced by
many stimuli and is considered a therapeutic funnel
because its activity appears to be required by other ther-
apeutic molecules [5]. Induction of HO-1 expression
within the central nervous system (CNS) has been
demonstrated in rodent astrocytes, microglia/macro-
phages and neurons [6-8]. However, neurons constitu-
tively express primarily HO-2 under normal conditions
[9] and rodent astrocytes also have been shown to
express HO-2 [10]. Clinically, up-regulated HO-1
expression appears to be beneficial in preventing organ
transplant rejection [11], although prolonged HO-1
expression in ischemic and traumatic brain injury lacked
a conclusively beneficial effect [12]. Furthermore, a poly-
morphism in the HO-1 gene promoter region, with
longer vs. shorter GT(n) repeats, may be associated with
susceptibility to ischemic events [13]. On the other
hand, suppression of HO-1 expression was found to be
beneficial in brain hemorrhage [14] and a potential ther-
apeutic intervention in Alzheimer’s disease [15]. Addi-
tionally, HO-1 deficiency in humans results in severe
abnormal growth and development [16].
The cytotoxic free radical nitric oxide (NO) plays an
important pathogenic role in many neurodegenerative
diseases [17-19]. In interleukin (IL)-1b-activated human
astrocytes, robust NO production generated by inducible
NO synthase (iNOS) has been shown to be either detri-
mental [20] or beneficial [21] depending on various cir-
cumstances. In the presence of the reactive oxygen
species (ROS) superoxide (O2
-), NO combines with O2
-
to form the highly toxic radical peroxynitrite (ONOO)
which can cause severe damage to neurons. The anti-
oxidant defense system present in astrocytes appears to
afford a protective effect on surrounding neurons. NO is
one among many stimuli that are capable of inducing
HO-1 expression [22]. This suggests that the oxidative
stress conditions induced by NO can be dampened by
the anti-oxidant property of HO-1 to confer an impor-
tant negative feedback loop.
A few reports have shown that HO-1 induction
decreases NO production and iNOS expression, includ-
ing in a rat model of glomerulonephritis [23], in a
human intestinal epithelial cell line [24] and in a lipopo-
lysaccharide (LPS)-induced mouse macrophage cell line
RAW264.7 [25]. Increased HO-1 and reduced iNOS
expression were also observed in spontaneously hyper-
tensive rats but without a cause-effect relationship being
established [26]. As our research laboratory has been
interested in the role of glial cells in neuropathogenesis
and host defense of the brain in this study we tested the
hypothesis that hemin would induce expression of HO-
1 ,w h i c hi nt u r nw o u l di n h i b i ti N O Sa n dN Op r o d u c -
tion in human astrocytes stimulated with the pro-
inflammatory cytokine IL-1b. Although several signaling
pathways are activated by IL-1b in astrocytes, we
focused on mitogen activated protein kinases (MAPKs)
to determine if the effect of hemin on IL-1b-stimulated
astrocytes is mediated through a MAPK signaling path-
way. We also looked into the possible effects of hemin
on IL-1b-stimulated cytokine and chemokine production
to assess whether HO-1 also dampens the production of
these inflammatory mediators.
Methods
Reagents
The following reagents were purchased from the indi-
cated sources: hemin (ferriprotoporphyrin IX chloride)
and Sn (IV) Protoporphyrin IX dichloride (SnPP, 8,13-
Bis(vinyl)-3,7,12,17-tetramethyl-21H,23H-porphine-2,18-
dipropionic acid tin(IV) dichloride) (Frontier Scientific,
Logan, UT); IL-1b, tumor necrosis factor (TNF)-a,
CXCL10, Human iNOS Quantikine ELISA Kit, anti-
human TNF-a and CXCL10 antibodies (R&D Systems,
Minneapolis, MN); anti-p38 and -extracellular signal-
regulated kinase 1 and 2 (ERK1/2 or p44/42) MAPK
antibodies (Cell Signaling, Beverly, MA); SB203580 (an
inhibitor of p38 MAPK) and U0126 (an inhibitor of
MAP kinase kinase [MEK]1/2, upstream of ERK1/2)
(EMD Biosciences, La Jolla, CA); mouse anti-HO-1 anti-
body (Assay Designs, Ann Arbor, MI); RNase inhibitor,
SuperScript™ III reverse transcriptase and alamarBlue®
(Invitrogen, Carlsbad, CA); DNase (Ambion, Austin,
TX); oligo (dT)12-18 (Promega, Madison, WI); SYBR®
Premix Ex Taq™ (Takara, Madison, WI); SYBR® Advan-
tage® qPCR premix (ClonTech, Mountain View, CA);
dNTPs (GE Healthcare, Piscataway, NJ); rabbit
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nology, Santa Cruz, CA); rabbit anti-GFAP (glial fibril-
lary acidic protein, Dako, Carpinteria, CA); LentiORF™
pLEX-MCS vector (Open Biosystems, Huntsville, AL);
Fugene 6 (Roche, Indianapolis, IN); M-PER (Thermo
Fisher Scientific, Rockford, IL); Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM), bovine serum albumin (BSA),
and 3,3′-diaminobenzidine, 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) (Sigma-
Aldrich, St. Louis, MO); acrylamide/bis-acrylamide gel
and protein assay (Bio-Rad, Hercules, CA); CDP-Star
substrate (Applied Biosystems, Foster City, CA); K-Blue
substrate (Neogen, Lexington, KY); heat-inactivated fetal
bovine serum (FBS, Hyclone, Logan, UT).
Preparation of hemin and SnPP
Both hemin and SnPP were dissolved in 0.2 N NaOH,
adjusted to physiological pH 7.4 with 1 N HCl,
aliquoted in dark brown tubes and frozen at -80°C.
Astrocyte cultures
Astrocytes were prepared from 16- to 22-week-old
aborted human fetal brain tissues obtained under a pro-
tocol approved by the Human Subjects Research Com-
mittee at our institution. Brain tissues were dissociated
and resuspended in DMEM containing penicillin (100
U/ml), streptomycin (100 μg/ml), gentamicin (50 μg/ml)
and Fungizone® (250 pg/ml) and plated onto poly-L-
lysine (20 μg/ml)-coated 75-cm
2 flasks at a density of
80-100 × 10
6 cells/flask and incubated at 37°C in a 6%
CO2 incubator. Culture medium was changed at a
weekly interval. On day 21, flasks were shaken at 180-
200 rpm for 16 h followed by trypsinization with 0.25%
trypsin in HBSS for 30 min. After adding FBS (final con-
centration 10%), centrifugation and washing, cells were
seeded into new flasks with DMEM followed by medium
change after 24 h. The subculture procedure was
repeated four times at a weekly interval to achieve
highly purified astrocyte cultures (99% of cells reacted
with GFAP antibody) which were plated onto 60-mm
petri dish (0.6 to 1 × 10
6 cells/dish), 6- or 12-well
(10
6 cells/well) or 48-well (10
5 cells/well) plates for
protein collection, RNA extraction or ELISA assay.
Cell culture treatment conditions
Astrocyte culture medium was replaced with DMEM
without serum prior to SnPP or hemin treatment. The
final serum concentration of 6% was restored at 3 h
after the last hemin treatment unless noted. The con-
centrations of SnPP or hemin used throughout this
s t u d yd i dn o ti n d u c et o x i c i t yt oa s t r o c y t ec u l t u r e sa s
verified by MTT, trypan blue dye exclusion and alamar-
Blue® assays. All experiments containing SnPP or hemin
treatment were conducted in the dark with a dim light
to minimize inactivation of these compounds. Cell
culture plates or petri dishes were kept in a dark box to
prevent light exposure.
Cell viability assay
To determine the effect of hemin or SnPP on astrocyte
viability a MTT assay, which provides quantitative
assessment of mitochondrial integrity [transformation
of tetrazolium salt via mitochondrial succinic dehydro-
genases to formazan crystals (purple)], was used. After
treatment of astrocytes with hemin or SnPP, MTT
(final concentration of 1 mg/ml) was added to cell
cultures for 4 h followed by addition of lysis buffer
(20% SDS [w/v] in 50% N,N-dimethyl formamide, pH
4.7, adjusted with 2.5% acetic acid and 1 N HCl [32:1])
for 16 h. Cell lysate was collected and absorbance was
read at 600 nm (Molecular Devices, Sunnyvale, CA) to
reflect possible cytotoxicity caused by treatment.
Another cell proliferation and cytotoxicity assay using
alamarBlue®, in which the living cells convert the non-
toxic, cell permeable and non-fluorescent resazurin
(blue) to red-fluorescent resorufin (red), was measured
at Ex 560 nm and Em 590 nm to verify cell viability.
Enzyme-linked immunoabsorbent assay (ELISA)
After treatment, astrocyte culture supernatants were col-
lected for ELISA measurement [27] of cytokines and
chemokines. In brief, 96-well ELISA plate pre-coated
with mouse anti-human cytokine/chemokine antibody
(2 μg/ml) overnight at 4°C was blocked with 1% BSA in
PBS for 1 h at 37°C. After washing with PBS with
Tween 20, culture supernatants and a series of dilution
of cytokines/chemokines (as standards) were added to
wells for 2 h at 37°C. Goat anti-human cytokine/chemo-
kine detection antibody was added for 90 min followed
by addition of donkey-anti-goat IgG horseradish peroxi-
dase conjugate (1:10,000) for 45 min. A chromogen sub-
strate K-Blue was added at room temperature for color
development which was terminated with 1 M H2SO4.
The plate was read at 450 nm and cytokine/chemokine
concentrations were extrapolated from the standard
concentration curve.
NO assay
After treatment, astrocyte culture supernatants were col-
lected to measure nitrite (NO2
-) release using Griess
reagent, which reflects NO production in cultures as
previously described [20]. In brief, Griess reagent
( f r e s h l ym i x e db e f o r eu s e )c onsisting of equal volumes
of 0.1% naphthylenediamine dihydrochloride in distilled
H2O and 1% sulfanilamide and 6% H3PO4 in distilled
H2O, was added in equal volume to astrocyte culture
supernatants. After 10 min incubation at room tempera-
ture, the mixtures were read with a microplate reader at
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- level was extrapolated from a stan-
dard curve generated with a series of concentrations of
sodium nitrite (NaNO2,1 - 6 2 . 5μM). The detection limit
for NO2
- was 0.5 μM.
iNOS immunoassay
To determine the iNOS concentration in cell lysates,
astrocyte cultures (in 12-well plate) were untreated or
pretreated with hemin for 24 h prior to IL-1b treatment
for 72 h. Cell lysates were collected and assayed accord-
ing to manufacturer’s protocol.
Immunocytochemical reaction
After treatment, astrocyte cultures plated onto chamber
slides were fixed with 4% paraformaldehyde followed by
washing with PBS and incubation with 10% normal don-
key serum in PBS for 1 h at room temperature (RT).
Primary mouse anti-human HO-1 or rabbit anti-GFAP
antibodies (1:1000, 1 mg/ml) was added and incubated
o v e r n i g h ta t4 ° C .A f t e rw a s h ing, secondary antibody
(rhodamine- or FITC-conjugate) was added for 1 h at
RT followed by viewing under fluorescent microscope.
pLEX HO-1 vector transfection
Astrocyte cultures were transfected with 1 μgp L E Xv e c t o r
containing either blank or human HO-1 sequences under
a cytomegalovirus (CMV) promoter in Fugene 6 reagent
for 72 h prior to IL-1b treatment for 72 h. Total cell pro-
teins were collected with M-PER, aliquoted and mixed
with 2× sample buffer before being stored at -20°C.
Real-time polymerase chain reaction
Total RNA extracted from astroyctes after treatment
was treated with DNase and reverse transcribed to
cDNA with oligo (dT)12-18, random hexmer, dNTPs,
RNase inhibitor and SuperScript™ III reverse transcrip-
tase. Mixtures of diluted cDNA, primers and SYBR® Pre-
m i xE xT a q ™ or SYBR® Advantage® qPCR premix were
subjected to real-time PCR (Stratagene, La Jolla, CA)
according to manufacture’s protocol. Primer sequences
were sense 5′- TCAACATCCAGCTCTTTGAGGA-3′
and antisense 5′-AGTGTAAGGACCCATCGGAGAA-3′
for HO-1, sense 5′- TTATGACTCCCAAAAGTTT-
GACCA-3′ and antisense 5′- CCGTCAGTTGGTAGGT-
TACTGTTG-3′ for iNOS, and sense 5′-G A C C T G C T G
GATTACATCAAAGCACT-3′ and antisense 5′-
CTTTGGATTATACTGCCTGACCAAGG-3′ for HPRT
(hypoxanthine phosphoribosyltransferase).
Western blot
Cell lysates collected after treatment were electrophor-
ezed in 12% (for HO-1, HO-2 or MAPKs) or 7.5% (for
iNOS) acrylamide/bis-acrylamide, electrotransfered onto
nitrocellulose membrane and probed with antibodies for
HO-1, HO-2, iNOS or MAPKs (p38 and p44/42) fol-
lowed by alkaline phosphatase-conjugated secondary
antibodies with chemiluminescence detection using
Kodak Image Station (Carestream Health (formerly
Kodak), New Heaven, CT).
Statistical analysis
Data are expressed as mean ± SD or SE as indicated. For
comparison of means of multiple groups, analysis of var-
iance (ANOVA) was used, followed by Fisher’s PLSD test.
Results
Inhibition of iNOS mRNA expression and NO production
To test the hypothesis that hemin would inhibit iNOS
expression, human astrocyte cultures were pretreated
with hemin for 24 h followed by IL-1b treatment for 4
h or 24 h for total RNA isolation. Marked inhibition of
iNOS mRNA expression was observed in hemin-pre-
treated cells (Fig. 1A). In the same hemin treatment
paradigm followed by stimulation of astrocytes with IL-
1b for 72 h, a similar inhibitory effect of hemin was
observed when culture supernatants were assayed for
NO (Fig. 1B).
Hemin-induced HO-1 expression in human astroyctes
To confirm that hemin induces HO-1 in human astro-
cytes, cells were treated with hemin (20 μM) for 24, 48
and 72 h and HO-1, HO-2 and b-actin (as internal con-
trol) expression were assessed by western blot (Fig. 2A).
Induction of HO-1 expression by hemin was robust at
24 h and decreased over time, while HO-2 was constitu-
tively expressed in human astrocytes. No effect of hemin
on b-actin expression was observed. There was no cyto-
toxicity induced by hemin measured by MTT (101.95 ±
2.59% of untreated control) or alamarBlue (100.11 ±
3.35% of untreated control) assays. Immunocytochemical
reaction also demonstrated no nuclear fragmentation
(DAPI staining at 1 μg/ml) in hemin-treated astrocytes
indicating no cytotoxicity. It also showed that all astro-
cytes were GFAP positive and hemin induced robust
HO-1 expression, which was co-localized with many, if
not all, GFAP positive astrocytes (Fig. 2B).
Blockade of the inhibitory effect of hemin on NO
production
Pretreatment of human astrocytes with SnPP significantly
ameliorated hemin-mediated inhibition of IL-1b-induced
NO production, although SnPP did not fully restore the
NO level when 20 μM hemin was used (Fig. 3) suggesting
involvement of additional mechanism(s). Pretreatment
with SnPP appeared to enhance IL-1b-induced NO pro-
duction suggesting that SnPP itself had no effect on NO
production, but rather had exerted inhibition on induci-
ble HO-1 and the constitutive HO-2 [28,29].
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Hemin treatment inhibited IL-1b-induced iNOS
expression in human astrocytes (Fig. 4A, B). Further-
more, hemin-induced HO-1 expression was further
enhanced in the presence of IL-1b ( F i g .4 A ) .T h ec o n -
stitutively expressed HO-2 was minimally changed by
hemin and IL-1b treatment while no effect on b-actin
expression was found (Fig. 4A). Pretreatment with
the HO-1 inhibitor SnPP significantly reversed the
inhibitory effects of hemin on IL-1b-induced iNOS
expression (Fig. 4B). As mentioned above, SnPP also
enhanced IL-1b-induced iNOS indicating that SnPP
not only inhibited HO-1, but also may have relieved
the inhibitory effect of endogenous components, e.g,
HO-2, exerted upon iNOS.
Figure 2 Induction of HO-1 expression. A) Cell lysates collected from hemin (20 μM)-treated human astrocyte cultures for 24, 48 and 72 h
were electrophorezed, transferred to nitrocellulose membrane and probed for HO-1, HO-2 or b-actin (as internal control) expression. C, untreated
control. B) Immunocytochemical reaction of hemin (20 μM)-treated astrocyte cultures (72 h) for HO-1 (red) or GFAP (green) and counter stained
with DAPI (blue) was shown.
Figure 1 Inhibition of iNOS expression and NO production in human astrocytes. Human astrocyte cultures were treated with hemin (10
and 20 μM) for 24 h prior to IL-1b (10 ng/ml) exposure for A) 4 h or 24 h for RNA extraction to measure iNOS mRNA expression or B) 72 h to
measure NO concentration in culture supernatants. Data presented in A) are representative of 3 separate experiments and in B) are mean ± SE
of triplicates from different brain tissue specimens. ** p < 0.01 vs. untreated control (C);
††p < 0.01 vs. IL-1b alone.
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To further investigate the role of HO-1 in iNOS expres-
sion, human astroyctes were transfected with a pLEX
expression vector containing human HO-1 sequences
under a CMV promoter for 72 h. The transfection effi-
ciency was approximately 30% in human primary astro-
cytes and this treatment was associated with expression
of HO-1, while treatment with a blank sequence-con-
taining vector was not (Fig. 5). In combination with
IL-1b, HO-1 expression was further enhanced (Fig. 5).
IL-1b-induced iNOS expression was markedly downre-
gulated by overexpression of HO-1, further demonstrat-
ing the inhibitory effect of HO-1 on iNOS expression
(Fig. 5). No effect on b-actin expression was found.
Immunocytochemical reaction of IL-1b-induced HO-1
expression
Although IL-1b treatment induced undetectable HO-1
expression by western blot, induction of HO-1 was
detectable by immunocytochemical reaction (Fig. 6),
possibly due to different detection sensitivities between
these methods.
Involvement of p38 MAPK
Because IL-1b is known to trigger activation of both p38
and ERK1/2 (p44/42) MAPK signaling pathways in
human astrocytes [30], we studied the effects of specific
inhibitors of p38 (SB203580) and ERK1/2 (p44/42)
Figure 4 Blockade of hemin-induced iNOS inhibition. A) Culture lysates (40 μg) collected from human astrocytes treated with hemin (20 μM)
for 24 h prior to IL-1b (10 ng/ml) exposure for 72 h were electrophorezed, transblotted to nitrocellulose membrane and probed for iNOS, HO-1,
HO-2 or b-actin (as internal control) expression. B) Human astrocytes were pretreated with SnPP (10 μM) for 3 h prior to hemin (10 and 20 μM)
treatment for 24 h followed by IL-1b (10 ng/ml) exposure for 72 h. Cell lysates were collected, centrifuged and assayed for iNOS expression by
ELISA. Sensitivity of iNOS ELISA was 0.05-0.46 U/ml. Data presented are mean ± SE of triplicates from 2 separate experiments using different
brain tissue specimens. ** p < 0.01 vs. untreated control (C);
††p < 0.01 vs. IL-1b alone;
§§p < 0.01 vs. corresponding hemin+IL-b.
Figure 3 Blockade of hemin-induced NO inhibition.H u m a n
astrocyte cultures were pretreated with SnPP (10 μM) for 3 h prior to
hemin (10 and 20 μM) treatment for 24 h followed by IL-1b (10 ng/
ml) exposure for 72 h before measuring NO concentration in culture
supernatants. Data presented are mean ± SE of triplicates from 3
separate experiments using different brain tissue specimens.
** p < 0.01 vs. IL-1b alone;
††p < 0.01 vs. corresponding hemin+IL-1b.
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7A, we found that NO production was dependent on
p38 but not p44/42 MAPK activation. The inactive
inhibitor of p38 MAPK (SB202474) had no effect on
NO production (data not shown). Treatment with these
inhibitors alone (0.3-30 μM) did not induce astrocyte
toxicity by MTT or alamarBlue assay (data not shown).
Because hemin treatment inhibited IL-1b-induced NO
production, we investigated the effect of hemin on IL-
1b-induced p38 MAPK activation. Hemin alone
minimally activated MAPK, however, it markedly down-
regulated IL-1b-induced p38 but not p42 MAPK
activation (Fig. 7B), suggesting the involvement of p38
MAPK in the inhibitory effects of hemin on NO produc-
tion. No effect on b-actin expression was found (Fig. 7B).
Inhibition of cytokine/chemokine production
After establishing the inhibitory effect of hemin on
iNOS expression and NO production, we investigated
whether hemin also would suppress the production of
other inflammatory mediators, i.e. cytokines and chemo-
kines, produced by IL-1b-stimulated human astrocytes.
Previously, we found that IL-1b-activated human astro-
cytes release TNF-a and CXCL10 [27]. Following hemin
pretreatment, IL-1b- induced TNF-a and CXCL10 pro-
duction was down-regulated (Fig. 8A, C) and this inhibi-
tion was blocked significantly by SnPP (Fig. 8B, D)
suggesting the involvement of HO.
Figure 6 Immunocytochemical reaction of IL-1b-induced HO-1 expression. Human astrocyte cultures were pretreated with hemin for 24 h
prior to IL-1b exposure for 72 h followed by fixation and immunocytochemical reaction for HO-1. Untreated control (C), blue - DAPI nuclei
staining and red - HO-1 reaction.
Figure 5 Effects of HO-1 overexpression. Human astrocyte
cultures were transfected with 1 μg pLEX expression vector
containing blank (pMock) or human HO-1 (pHO-1) sequences under
a CMV promoter in Fugene 6 reagent for 72 h prior to IL-1b
exposure for 72 h followed by protein collection with M-PER. Equal
amount of proteins were loaded onto 12% (for HO-1) or 7.5% (for
iNOS) acrylamide/bis gel for electrophoresis, transblotted onto
nitrocellulose membrane and probed with mouse anti-HO-1 or
rabbit anti-iNOS or anti-b-actin (as internal control) antibodies. C;
untreated control.
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In the current study, we demonstrated that hemin robustly
induces HO-1 expression in human astrocytes and that
pretreatment with hemin significantly inhibited IL-1b-
induced iNOS expression, NO production, and TNF-a as
well as CXCL10 release. Furthermore, we showed that this
inhibitory effect was markedly reversed by the HO activity
inhibitor tin-protoporphyrin (SnPP), suggesting the invol-
vement of an HO-mediated mechanism. IL-1b-induced
NO production is known to be p38 MAPK-dependent,
and we found that hemin treatment down-regulated IL-
1b-induced p38 MAPK, suggesting the involvement of this
intracellular signaling pathway in hemin’si n h i b i t o r y
action. Interleukin-1b activates astrocytes robustly to pro-
duce inflammatory mediators including cytokines, chemo-
kines, and NO [27,31,32], which may contribute to
autocrine and paracrine effects on neighboring neuronal
and glial cells. Nitric oxide is one of the stimuli known to
induce HO-1 [33], which exerts a possible feedback inhibi-
tion on NO, as seen in this study.
The role of HO-1 under different experimental para-
digms and disease conditions has been found to be
either beneficial or damaging and its protective func-
tion is debatable. Due to inflammatory mediator pro-
duction by IL-1b-activated astrocytes leading to
potential harmful consequences, our hypothesis was
that hemin induction of anti-inflammatory HO-1
expression in IL-1b-activated astrocytes would be ben-
eficial. The results of this study support the notion
that hemin inhibits IL-1b-induced iNOS expression
and NO production in human astrocytes and are in
agreement with findings of others using cell types not
found within the nervous system [23-25]. The interplay
and negative feedback interaction between HO-1 and
iNOS that we found in this study has been observed in
the study of glomerulonephritis [23]. This phenom-
enon has also been suggested to involve a reduction of
t h ea v a i l a b l eh e m ep o o l[ 3 4 ]f o rd en o v oi N O Ss y n t h -
esis, CO interacting with iNOS heme moiety [35] and
iron down-regulation of iNOS transcription [36].
In this study we also confirmed the finding that NO
production is dependent on p38 MAPK [37]. The down-
regulation of p38 MAPK by hemin pretreatment sug-
gests involvement of the p38 MAPK signaling pathway
in the inhibitory effect of hemin on IL-1b-induced NO
production. In the murine macrophage cell line
RAW264.7, hemin was found to attenuate LPS-induced
NF-B activation [38]. Silencing HO-1 was found to
enhance LPS-induced nuclear factor (NF)-B activation
suggesting an inhibitory role of HO-1 on NF-B activa-
tion [39] which is also required downstream for NO
production [40]. Thus, hemin could also inhibit IL-1b-
stimulated downstream NF-B activation in astrocytes.
Our demonstration that SnPP blocks hemin-suppressed
Figure 7 Involvement of p38 MAP kinase. A) Human astrocytes were pretreated for 1 h with the p38 MAPK inhibitor SB203580 or MEK1/2
inhibitor U0126 (3, 10, 30 μM) prior to IL-1b (10 ng/ml) exposure for 72 h. Culture supernatants were collected to measure NO levels by Griess
reagent. Data presented are mean ± SE of triplicates of 2-3 separate experiments using astrocyte cultures from different brain tissue specimens.
**p < 0.01 vs. untreated control (C);
††p < 0.01 vs. IL-1b alone. B) After replacing culture media with DMEM without serum, human astrocytes
were treated with hemin (20 μM) for 24 h prior to IL-1b (10 ng/ml) exposure for 30 min. Cell lysates were electrophorezed, transblotted to
nitrocellulose membrane and probed for p38 or p44/42 MAPK or b-actin (as internal control). Data presented are representative of 3 separate
experiments using different brain tissue specimens.
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Page 8 of 10IL-1b-induced inflammatory TNF-a and CXCL10 pro-
duction in human astrocytes corresponds well with the
finding that overexpression of HO-1 inhibited LPS-
induced TNF and IL-1b expression in THP-1 cells [39],
providing further evidence for the anti-inflammatory
effect of HO-1.
Several caveats and limitations in our study must be
acknowledged. The constitutive expression of HO-2 in
our human primary astrocytes may also have contribu-
ted to the inhibition of NO [41] as shown by non-
selective SnPP treatment on IL-1b. Another possible
explanation is that SnPP alters an unknown mechan-
ism leading to the enhancement of IL-1b-induced
iNOS expression and NO production in astrocytes.
Although there was no cytotoxicity detected by either
MTT or alamarBlue assays, we observed that hemin
treatment altered astrocytem o r p h o l o g yt oas m a l l e r
cell size without changing b-actin expression. We also
observed minor inhibition of GFAP expression by
hemin. Hemin-induced HO-1 expression was observed
in about 50% of astrocytes; this could be due to sub-
types of and/or delayed response among astrocytes in
cultures. Transfection of astrocytes with an HO-1
expression vector demonstrated the inhibitory effect of
HO-1 on iNOS, but potential mechanisms involving
byproducts from the HO reaction, i.e., CO, iron, bili-
verdin and bilirubin, should not be ignored.
In conclusion, we have demonstrated in vitro the
r o b u s ti n d u c t i o no fH O - 1e x p r e s s i o ni nh u m a na s t r o -
cytes exposed to hemin. Induced HO-1 expression
exerts an inhibitory effect on iNOS expression and NO
production in IL-1b-stimulated human astrocytes and
the inhibitory effects of hemin are mediated mainly
through HO-1 induction and associated with reduced
activation of p38 MAPK. Extrapolation of these in vitro
human brain cell culture results to in vivo models
should be undertaken with caution as there are species
and response differences to be expected. However, these
f i n d i n g ss u p p o r tt h ec o n c e p tt h a tH O - 1e x p r e s s i o ni n
astrocytes is an antioxidant defense system in the face
of neuroinflammation.
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